Sign In
Buy NVS
$153.38
+4.45 (+2.99%)
At Close: Jun 23, 2026
Vanrafia can be seamlessly added to supportive care in IgAN and used as a foundational therapy with no requirement for a REMS (Risk Evaluation Mitigation Strategy) program1 Phase III data showed Vanra
Ad hoc announcement pursuant to Art. 53 LR Vanrafia can be seamlessly added to supportive care in IgAN and used as a foundational therapy with no requirement for a REMS (Risk Evaluation Mitigation Str
Novartis (NVS) Could Be a Great Choice
12:50pm, Wednesday, 02'nd Apr 2025
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Novartis (NVS) have what it takes?
Basel, March 31, 2025 – Novartis announced today the appointment of Karen Hale to the expanded role of Chief Legal and Compliance Officer for Novartis, effective April 14, 2025. She will continue to
Ad hoc announcement pursuant to Art. 53 LR New indication approximately triples eligible patient population, allowing Pluvicto® to be used after one androgen receptor pathway inhibitor (ARPI) and now
Here's Why Novartis (NVS) is a Strong Value Stock
10:40am, Friday, 28'th Mar 2025
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
5 Large Drug Stocks to Watch as Industry Recovers
07:50am, Tuesday, 25'th Mar 2025
Industry Description
Novartis to present new data at AAN, including seven-year disability outcomes and safety analysis of Kesimpta® in people with relapsing multiple sclerosis
Looking for Stocks with Positive Earnings Momentum? Check Out These 2 Medical Names
09:50am, Monday, 24'th Mar 2025
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Watch These 5 AI-Powered Healthcare Bigwigs for Portfolio Gains
09:45am, Monday, 24'th Mar 2025
Five AI-powered stocks have strong revenues and earnings growth potentials for 2025. These are: MDT, LLY, BSX, NVS, ABT.
FDA Approves Novartis Drug for Rare Kidney Disease Treatment
03:11pm, Friday, 21'st Mar 2025
Novartis wins FDA approval for the label expansion of Fabhalta for a third indication - treatment of adults with C3 glomerulopathy.
Novartis receives third FDA approval for oral Fabhalta® (iptacopan) - the first and only treatment approved in C3 glomerulopathy (C3G)
07:37pm, Thursday, 20'th Mar 2025
Phase III study showed sustained proteinuria reduction at one year with favorable safety1 Fabhalta is the only oral alternative complement pathway inhibitor thought to target the underlying cause of C
Novartis receives third FDA approval for oral Fabhalta® (iptacopan) – the first and only treatment approved in C3 glomerulopathy (C3G)
07:11pm, Thursday, 20'th Mar 2025
Novartis receives third FDA approval for oral Fabhalta ® (iptacopan) – the first and only treatment approved in C3 glomerulopathy (C3G)
Novartis Reports Updated Positive Data From Phase III SMA Program
10:35am, Thursday, 20'th Mar 2025
NVS reports new safety and efficacy data from the phase III program for its investigational OAV101 IT gene therapy for SMA patients.
Novartis scraps use of diverse panels for hires in US
08:45am, Wednesday, 19'th Mar 2025
Swiss drugmaker Novartis is ending its use of diverse panels for all of its hiring in the United States, the company told Reuters on Wednesday, citing the changing legal and policy landscape surroundi
